The Future of Intraparadneal Chemotherapy

I look at the history of intraparadneal chemotherapy as one in which the data have been compelling, but it's been relatively underutilized. Do you foresee this approach facing major headwinds because people just won't do IP therapy outside of larger centers or do you think other practitioners will get on board and adopt IP administration if the data are strong enough? This trial is more complex than a standard face to oral or IV drug administration, certainly. However, the outlook for patients with platinum resistant ovarian cancer in general is rather poor.